Navigation Links
VBI Provides Potential Targets to Diabetes Therapeutics

Virginia Bioinformatics Institute (VBI) Assistant Professor Biswarup Mukhopadhyay has provided important information for researchers designing drugs for type 2 diabetics in the// December 22, 2006, Journal of Biological Chemistry.

The information should in time help researchers to identify potential targets for docking inhibitors that will slow down, but not fully eliminate, the body's overproduction of glucose.

The study investigates ways to control the activity of phosphoenolpyruvate carboxykinase – a key enzyme involved in the metabolic pathway used by the human body to produce glucose. Phosphoenolpyruvate carboxykinase helps to control blood sugar levels during fasting. An overproduction of this enzyme, among other events, may lead to type 2 diabetes.

Mukhopadhyay remarked: "The research is a proof of concept study showing that it is possible to alter the activity of phosphoenolpyruvate carboxykinase without directly interfering with catalysis. Because the research pertains to surface residues on the protein molecule, this approach could be used to design a compound that can prevent the enzyme from participating in the overproduction of glucose in the liver of a person with type 2 diabetes."

He added: "Much work remains to be done to take this finding from proof of concept to a potential clinical application but we have at least demonstrated that the activity of the enzyme can be modulated by structural manipulation."

The group investigated the roles of three key amino acid residues and, more specifically, examined how changing each residue affected the enzyme's properties. The researchers concluded that it is possible to influence the activity of the enzyme from a site distinct from where the reaction takes place on the enzyme.

The research appeared in the article, "Roles of Asp75, Asp78, and Glu83 of GTP-dependent phosphoenolpyruvate carboxykinase from Mycobacterium smegmatis," by Christ
'"/>




Page: 1 2

Related medicine news :

1. Drug Spironolactone Provides Renal And Cardioprotection In Diabetic Patients
2. Neurobiology Provides Answers To Block Memory-Related Drug Cravings
3. London Hospital Provides Specialized Care For Pregnant Women
4. Breastfeeding Provides Added Protection To Babies
5. Far East Provides A Path To Contain Bird Flu
6. Direct To Home: Television Provides Powerful Fillip to Smoking Cessation Campaigns.
7. Latest Version of Echocardiography Provides Improved Pictures of the Heart
8. Hearing May Be Regained: Research Provides Hopes
9. Study Provides Evidence That Obesity Leads To A More Aggressive Ovarian Cancer
10. Food Safety Extension Specialist Provides Spinach E. coli Advice
11. A New Approach to Heart Bypass Surgery Provides Patients with One-stop Shopping
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: VBI Provides Potential Targets Diabetes Therapeutics

(Date:12/26/2014)... (PRWEB) December 26, 2014 Yisrayl Hawkins, Pastor ... an open letter in light of the Ferguson, Missouri unrest. ... of civil unrest and explains why it has only increased. ... mankind was even created. He says there is a very ... Yisrayl also says there is a set of rules, or ...
(Date:12/26/2014)... Orlando, FL (PRWEB) December 26, 2014 ... visitor health insurance in the USA, announced today a ... to assist members in choosing the right plan for ... take the complexity out of the selection process when ... premiums by age group with only a few clicks. ...
(Date:12/25/2014)... The microscopy market is estimated to grow ... million by 2019. Optical microscopy is the largest ... product segment is expected to show the fastest ... on nanotechnology, technological advancements, and increasing federal support ... Get Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html ...
(Date:12/25/2014)... 2014 The report “TS-1 (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... an anti-cancer drug which is typically used for treating ... used for treating gastric cancer and pancreatic cancer. TS-1 ... drug was first approved in 1999 in Japan for ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
... June 6 The makers of the WaveSense(TM),line of ... the WaveSense Presto and WaveSense KeyNote Pro Blood Glucose,Monitoring ... with premium,features that consumers can buy at a value ... with added features for increased safety., The Presto ...
... University of Cincinnati (UC), says that cases of Amyotrophic ... first Persian Gulf War were caused by certain events ... exposure and illness is not as widespread as previously ... July issue of Neuroepidemiology. , Ronnie Horner, PhD, lead ...
... Carriage Services, Inc.,(NYSE: CSV ) today announced ... which can be found on Carriage,s website at, ... Profile includes updated,discussions of Carriage,s business, operating and ... The Company & Investment Profile is being ...
... part of its,ongoing efforts to alleviate human ... and Development (LIFE), recently shipped an,entire forty-foot ... Somalia., In partnership with California-based RICE ... Agency for the Horn,of Africa (ARAHA), two ...
... Grubb & Ellis,Healthcare REIT, Inc. today announced ... consisting of 22 office condominiums in,the Manchester-suburb of ... Nutfield Professional Center consists of,approximately 70,000 square feet ... Center was renovated in 1990 and again in ...
... 5 joint statement, the,presiding bishops of the Evangelical Lutheran ... citizens to pray for peace in Sudan, and,they called ... there., The Rev. Mark S. Hanson of the ... Church made their comments in a public statement,following a ...
Cached Medicine News:Health News:New WaveSense Presto(TM) and Pro(TM) Glucose Meters to Simplify Testing 2Health News:UC research shows risk of ALS exposure in Gulf War veterans is time limited 2Health News:Carriage Services Updates Company & Investment Profile 2Health News:Grubb & Ellis Healthcare REIT Acquires Nutfield Professional Center in Derry, N.H. 2Health News:Grubb & Ellis Healthcare REIT Acquires Nutfield Professional Center in Derry, N.H. 3Health News:Lutheran, Episcopal Church Presiding Bishops Urge Prayers for Peace in Sudan 2
(Date:12/24/2014)... N.Y. , Dec. 24, 2014 Kinex ... dosed with KX2-361 at Roswell Park Cancer Institute. ... small molecule drug that has shown potent inhibitory activity ... including those that are resistant to Temozolomide (T98G), the ... glioma. In a well-established brain tumor mouse model, KX2-361 ...
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission ... ResMed (RMD) against BMC Medical. In a notice issued on ... found that ResMed,s patent on its humidifier was invalid. ... a "monumental win". "We are very excited with the ITC,s ... position that we have taken since the very beginning on ...
(Date:12/24/2014)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ), the ... Jennifer Hagerman , Pharm.D., AE-C, senior director of ... the president of the Michigan Pharmacists Association on Jan. ... Feb. 28, 2015, at the MPA Annual Convention and ... in Detroit, Michigan . Hagerman will ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3
... Aug. 21 Genetic testing can be,used to ... anticoagulant, according to research published in the,September 1, ... American Society of,Hematology. This result represents one of ... to guide personal medical care., Because individuals ...
... Randomized, Double-Blind Study Targets Biomarker-Defined Population, ... (Nasdaq: GNTA ) announced that the ... confirmatory Phase 3 trial of Genasense,(oblimersen sodium) ... as,AGENDA, is a randomized, double-blind, placebo-controlled study ...
Cached Medicine Technology:Genetics Determine Optimal Drug Dose of Common Anticoagulant 2Genetics Determine Optimal Drug Dose of Common Anticoagulant 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 2Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 4Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 5
The FastPack system is a state of the art, lab quality immunoassay system designed for rapid results. The FastPack system delivers lab-quality sensitivity at a fraction of the cost of laboratory....
... The Vitros ECi brings true ... to immunodiagnostic testing. Highly sensitive assays ... oncology and bone metabolism testing are ... under development. The Vitros ECi can ...
... Vitros 250 is a flexible ... in multiple environments small ... clinics and satellite locations. The ... dilution, and can be automated ...
... In an effort to improve on ... hormones, toxicology, abused drugs, and immunosuppressants ... 1991 which incorporates random access capabilities. ... has undergone several important changes in ...
Medicine Products: